Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Performance and safety of the ZygoFixU zygomatic implant system over the medium and long term

Official title: Prospective, Multicenter, European Clinical Investigation Evaluating the Short and Medium-term Performance and Safety of the Global D ZygoFixU Implant-prosthetic System

Run by Global D · NCT06960460 · Data updated 2026-11-12

This study will test ZygoFixU zygomatic implants to see if they last at least one year and are safe for adults with severe upper-jaw bone loss.

More Dental Implants trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment99 (estimated)
SponsorGlobal D
Industry-sponsored
Drugs / interventionsradiation
Locations3 sites (Toulouse, France and 2 other locations)
StatusRecruiting
StartedApril 10, 2025
Main results expectedSeptember 1, 2030
Study endsDecember 31, 2031
Registry record updatedJuly 2, 2025
Trial IDNCT06960460 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with completed maxillary growth who are partially or completely edentulous and have advanced maxillary atrophy (Cawood & Howell grades IV–VI) and who require placement of two or four zygomatic implants are ideal candidates.

Probably not a fit

Patients with adequate maxillary bone for standard implants, general contraindications to implant surgery, or serious medical comorbidities are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ZygoFixU range includes zygomatic implants, prosthetic components, and placement instruments that are similar in design to existing zygomatic systems but are not CE-marked. This is an open-label, non-comparative, prospective multicentre clinical investigation (class IIb) conducted at sites in France and Italy to document device performance and safety. Experienced oral and cranio-maxillofacial surgeons will place two or four implants per patient and patients will be followed with a primary endpoint of implant survival at one year postoperatively. The trial aims to demonstrate conformity with regulatory requirements under the MDR by collecting medium-term performance and safety data.

Why it matters

Potential benefit: If successful, the ZygoFixU system could provide a reliable option to restore function with fixed prostheses for patients who have severe maxillary bone loss.

How similar studies have gone: Zygomatic implants have an extensive published track record with generally high short- and medium-term survival rates, although this specific ZygoFixU device is unapproved and is being tested for conformity and safety.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult male or female patient,
* Patient whose growth and development of the maxillary bone is complete according to the investigator's judgement,
* Partially or completely edentulous patient,
* Patient with advanced maxillary atrophy (grades IV, V and VI according to the Cawood and Howell classification if used),
* Patient requiring implant treatment with Global D zygomatic implants (placement of two or four implants),
* Patient with acceptable oral opening (\>3 cm measured anteriorly),
* Patient able to read, understand and answer the quality-of-life questionnaire of the investigation and able to give consent,
* Patient agreeing to comply with the protocol design and to send his/her follow-up data, even in the event of a move,
* Patient having signed the consent form,
* In France, patient affiliated to a social security scheme.

Exclusion Criteria:

* Patient's state of health at enrolment:

  * General contraindications to implant surgery
  * Patient with zygomatic bone disease
  * Patient with untreated periodontal disease
  * Patient with acute or chronic infection in the implant placement area, or systemic infection, including acute or chronic maxillary sinusitis
  * Patient with acute or chronic inflammation in the implant placement area, or systemic inflammation,
  * Patient with uncontrolled diabetes (unstable blood glucose)
  * Patient with immunodeficiencies or using immunosuppressants
  * Patient who received radiation of more than +70 Gy to the head and neck region
  * Patient using intravenous aminobisphosphonates within 5 years prior to surgery
* Patient who are smokers (\>10 cigarettes/day) or with alcohol or drug addiction
* Person placed under legal protection (this includes guardianship, curatorship and legal protection).
* Pregnant or breastfeeding women

Where it's running

  • Cabinet dentaire Dr HADJ
    Marseille, France
    Recruiting
  • CCOI Toulouse
    Toulouse, France, France
    Not yet recruiting
  • Université de Bologne
    Bologne, Italie, Italy
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.